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A B S T R A C T
Background & aims: The relationship between mercury and autism spectrum disorders (ASD) has always been a
topic of controversy among researchers. This study aimed to assess the relationship between ASD and mercury
levels in hair, urine, blood, red blood cells (RBC), and brain through a meta-analysis.
Methods: A systematic search was performed in several databases including PubMed, ISI Web of Science,
Cochrane register of controlled trials, Google Scholar, Scopus, and MagIran until June 2017. Case-control studies
evaluating concentration of total mercury in diﬀerent tissues of ASD patients and comparing them to the healthy
subjects (control group) were identiﬁed. Necessary data were extracted and random eﬀects model was used to
calculate overall eﬀect and its 95% corresponding conﬁdence interval (CI) from the eﬀect sizes.
Results: A total of 44 studies were identiﬁed that met the necessary criteria for meta-analysis. The mercury level
in whole blood (Hedges = 0.43, 95% CI: 0.12, 0.74, P= 0.007), RBC (Hedges = 1.61, 95% CI: 0.83, 2.38,
P < 0.001), and brain (0.61 ng/g, 95% CI, 0.02, 1.19, P= 0.043) was signiﬁcantly higher in ASD patients than
healthy subjects, whereas mercury level in hair (−0.14 mg/g, 95% CI: −0.28, −0.01, P= 0.039) was sig-
niﬁcantly lower in ASD patients than healthy subjects. The mercury level in urine was not signiﬁcantly diﬀerent
between ASD patients and healthy subjects (0.51 mg/g creatinine, 95% CI: −0.14, 1.16, P= 0.121).
Conclusions: Results of the current meta-analysis revealed that mercury is an important causal factor in the
etiology of ASD. It seems that the detoxiﬁcation and excretory mechanisms are impaired in ASD patients which
lead to accumulation of mercury in the body. Future additional studies on mercury levels in diﬀerent tissues of
ASD patients should be undertaken.
1. Introduction
Autism spectrum disorders (ASD), as a general term refers to a
group of complex neurodevelopmental disorders present from early
childhood. These disorders are characterized, in varying degrees, by
diﬃculties in social interaction, verbal and non-verbal communication,
and repetitive behaviors [1]. Based on studies performed on identical
twins, factors such as genetics, environment, and their interactions are
important in the etiology of ASD. It was estimated from several previous
studies on advanced genetic testing of chromosomal abnormalities in
individuals diagnosed with an ASD that about 80% have negative ge-
netic test results, and among those with positive genetic test results only
about 7% had de novo mutations that could possible play an etiological
role in ASD [2,3].
Several neurotoxic environmental pollutants such as lead, mercury
(organic and inorganic), polychlorinated biphenyls, arsenic, and to-
luene are studied in the disease pathogenesis [4]. Exposure to mercury
occurs through dietary and non-dietary sources such as ﬁsh and other
seafood products, vaccines containing thimerosal, and dental amalgams
[5–7]. Mercury can directly pass the blood brain barrier and accumu-
late in high quantities specially in the visual cortex, cerebellum, and
spinal cord. Mercury also binds to the membranous organelles like
endoplasmic reticulum, mitochondria, and Golgi complex and disrupt
their function [8]. Children's central nervous system (CNS) is devel-
oping and therefore, more susceptible to neurotoxic eﬀects of heavy
metals than adults [9].
Referring to scientiﬁc literature, several studies have explored the
relationship between tissue mercury levels and ASD. A group of studies
found mercury as a risk factor in developing ASD [10–12]. However,
some studies did not ﬁnd any association between mercury and ASD
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[13–15]. Therefore, this study aimed to assess the relationship between
ASD and mercury levels in diﬀerent tissues (hair, urine, blood, RBC, and
brain) through a meta-analysis.
2. Materials and methods
2.1. Review design and search strategy
The study protocol was registered in PROSPERO, the international
database of registered systematic reviews with registration number:
CRD42016043439. We followed the PRISMA guidelines for the pro-
cessing and reporting the results of the meta-analysis [16]. A systematic
search was performed in several databases including PubMed, ISI Web
of Science, Cochrane register of controlled trials, Google Scholar,
Scopus, and MagIran until 25 June 2017.
The search strategy was as follow: PubMed was searched by key-
words: “Mercury”[Mesh] OR “Mercury Compounds”[Mesh] OR
“Mercury Isotopes”[Mesh]) AND (“Autism” OR “Autistic
Disorder”[Mesh] OR “Autism Spectrum Disorder”[Mesh]); ISI Web of
Science and Cochrane register of control trials were searched by key-
words: “Mercury” OR “Mercury Compounds” OR “Mercury Isotopes”)
AND (“Autism” OR “Autistic Disorder” OR “Autism Spectrum Disorder”;
Scopus and Google Scholar was searched by keywords: “mercury” AND
(“autism” OR “autistim spectrum disorder” OR “autistic disorder”).
Magiran; was searched by keywords: Mercury AND (Autism OR
“Autistic Disorder”). Search on the databases was separately performed
by all of the authors. Related studies were recognized and their title;
abstract; and if necessary full text were carefully read and evaluated.
References of the related articles were also searched in order to avoid
missing of the information.
2.2. Study selection
Case-control studies evaluating concentration of total mercury in
blood, red blood cells (RBC), hair, urine, nail, teeth, and brain of ASD
patients and comparing them to the healthy subjects (control group)
were identiﬁed. For each tissue, if possible, the mercury measurement
units were matched and then the studies were included in the meta-
analysis. Studies which did not measure the mercury levels in control
subjects and only report the tissue mercury concentration of ASD pa-
tients were excluded.
2.3. Data extraction and quality assessment
Data of the selected studies were extracted: the ﬁrst author's last
name, year of publication, origin, subjects age and gender, number of
cases and controls, tissues in which mercury was measured, method of
measurement, and mean ± standard deviation (SD) of mercury con-
centration. Two authors (AH and NR) separately extracted the data and
discussed to reach a consensus.
The quality of studies was assessed using the 9-star Newcastle-
Ottawa scale; in which a study was judged based on the following
perspectives: selection of study groups (case and control), compar-
ability of the groups, and ascertainment of exposure [17]. The full
score was 9 stars; scores 7–9 stars were deﬁned as high-quality and
scores <7 as low-quality studies. Two authors (TJ and AAF) sepa-
rately assessed the quality of studies and discrepancies was resolved
by consensus.
2.4. Statistical analyses
To evaluate the eﬀect size for each study, mean ± SD of total
mercury concentration in ASD and control groups was used. Random
eﬀects model was used to calculate overall eﬀect and its 95% corre-
sponding conﬁdence interval (CI) from the eﬀect sizes. Therefore, we
could consider the between-study variation [18,19]. For concentration
of mercury in hair, urine, and CNS, un-standardized method was em-
ployed to calculate the mean diﬀerence and 95% CI; while the Hedges’g
method (bias corrected standardized mean diﬀerence and its 95% CI)
was used for mercury levels in the whole blood and RBC, because
matching the mercury measurement units was not possible [20]. The
overall eﬀect was separately calculated for each tissue. Subgroup ana-
lysis based on the origin of the studies was performed to consider the
possible source of heterogeneity. The statistical heterogeneity between
the studies was assessed by I-squared (I2, ranged from 0 to 100%) and
Cochran's Q test [21,22]. Inﬂuence analysis was also performed to ex-
plore if the overall eﬀects depend on a particular study or group of
studies. Publication bias was evaluated by visual inspection of Begg’s
funnel plot asymmetry and Egger's test [23,24]. Statistical analyses
were performed using Stata, version 11.2 (Stata Corp, College Station,
TX, USA). P values less than 0.050 were considered statistically sig-
niﬁcant.
3. Results
3.1. Study selection and identiﬁcation
A total number of 2185 studies were found by our systematic search
on the mentioned databases. We excluded 998 duplicate studies and
1057 irrelevant topics. In the remained 130 articles, 85 reviews and
clinical trials were also excluded. Finally, we found 44 case-control
studied [10–15,25–62] in which the concentration of mercury was
compared between ASD and normal subjects. Fig. 1 shows the search
process. In 2 studies [9,63], mercury level was measured in children
tooth enamels and in 1 study [43], it was measured in nails. Due to the
lack of data, we did not perform meta-analysis on these tissues.
According to the 9-star Newcastle-Ottawa scale, 36 studies
[10–15,25–28,30–44,46,47,49,51,52,54,56–62] were classiﬁed as high-
quality studies (score ≥7) and 6 studies [29,45,48,50,53,55] as low-
quality studies (score <7; Table 1).
3.2. Association between mercury levels of diﬀerent tissues and autism
3.2.1. Hair
Mercury status in hair had been compared in 23 studies with 1038
ASD patients and 933 healthy subjects (Table 1). Results of meta-ana-
lysis on these studies demonstrated that mercury concentration was not
signiﬁcantly diﬀerent in the hair of ASD patients comparing to healthy
subjects (Fig. S1: 0.63 mg/g, 95% CI: −0.21, 1.46, P= 0.141). The
Egger's test and Begg's funnel plot showed that there was no publication
bias among the studies (Egger's test P= 0.773). According to I2
(97.4%) and Cochrane Q test (P < 0.001), there was heterogeneity
between the studies. Inﬂuence analysis showed that the heterogeneity
belonged to the studies of Fido and Al-Saad [29], Yassa [50], and
Hodgson et al. [48]. The analysis was repeated again without the
mentioned 3 studies; and the results showed that concentration of
mercury in the hair of ASD patients was signiﬁcantly lower than
healthy subjects (Fig. 2: −0.14 mg/g, 95% CI: −0.28, −0.01,
P= 0.039). The between studies heterogeneity was also removed
(I2 = 0.0% and Cochrane Q test P= 0.505).
3.2.2. Urine
The concentration of mercury in urine had been evaluated in 8
studies with 491 ASD patients and 417 healthy subjects (Table 1). The
results showed that the concentration of mercury in the urine was not
signiﬁcantly diﬀerent between ASD patients and healthy subjects (Fig.
S2: 1.80 mg/g creatinine, 95% CI:−0.10, 3.70, P= 0.063). There was
no publication bias among the studies according to the Begg's funnel
plot and Egger's test (Egger's test P= 0.274). The between studies
heterogeneity was high due to I2 (92%) and Cochrane Q test
(P < 0.001). Inﬂuence analysis showed that the heterogeneity be-
longed to the study of Metwally et al. [53]. Data was reanalyzed
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without this study and the heterogeneity was reduced (I2 = 24.9% and
Cochrane Q test P= 0.239). The new results also demonstrated that the
concentration of mercury in the urine was not signiﬁcantly diﬀerent
between ASD subjects and healthy ones (Fig. 3: 0.51 mg/g creatinine,
95% CI: −0.14, 1.16, P= 0.121).
3.2.3. Whole blood
Mercury concentration in the whole blood was measured in 16
studies with 1239 ASD patients and 1039 healthy subjects (Table 1).
Results demonstrated that blood level of mercury was signiﬁcantly
higher in ASD patients than healthy subjects (Fig. S3: Hedges = 1.13,
95% CI: 0.22, 2.04, P= 0.014). There was no publication bias among
the studies according to the Begg's funnel plot and Egger's test (Egger's
test P= 0.201). The between studies heterogeneity was high due to I2
(91.8%) and Cochrane Q test (P < 0.001). Considering the inﬂuence
analysis, the study of Yassa [45] and the study of Mostafa and Al-
Ayadhi [55] were the major source of heterogeneity. After excluding
the mentioned studies, the heterogeneity was removed (I2 = 22.4% and
Cochrane Q test P= 0.211). The new results showed that the con-
centration of mercury was signiﬁcantly higher in ASD patients com-
pared to the healthy subjects (Fig. 4: Hedges = 0.43, 95% CI: 0.12,
0.74, P= 0.007).
3.2.4. RBC
The concentration of mercury was considered in 5 studies with 251
ASD patients and 215 healthy subject (Table 1). Result of meta-analysis
on these studies showed that the concentration of mercury in the RBC of
ASD patients was signiﬁcantly higher than healthy subjects (Fig. S4:
Hedges = 1.29, 95% CI: 0.35, 2.24, P= 0.007). There was no pub-
lication bias according to the Begg's funnel plot and Egger's test (Egger's
test P= 0.062). The between studies heterogeneity was high due to I2
(65.6%) and Cochrane Q test (P= 0.020) and according to inﬂuence
analysis, the heterogeneity belonged to the study of Adams et al. [45].
The new analysis re-performed without the mentioned study re-
presented that the concentration of mercury in the RBC of ASD patients
was signiﬁcantly higher than healthy subjects (Fig. 5: Hedges = 1.61,
95% CI: 0.83, 2.38, P < 0.001). The between studies heterogeneity was
reduced according to I2 (29.5%) and Cochrane Q test (P= 0.235).
3.2.5. Brain
Three studies with 16 ASD patients and 20 healthy subjects mea-
sured the concentration of mercury in brain tissue (Table 1). Results of
meta-analysis on these studies demonstrated that the concentration of
mercury was signiﬁcantly higher in ASD patients than healthy subjects
(Fig. 6: 0.61 ng/g, 95% CI: 0.02, 1.19, P= 0.043). According to the
Begg's funnel plot and Egger's test (Egger's test P= 0.336), there was no
publication bias. Results of I2 (0.0%) and Cochrane Q test (P= 0.860)
showed that there was no signiﬁcant heterogeneity between the studies.
3.3. Subgroup analyses
Results of subgroup analyses based on continents are shown in
Table 2. Concentration of mercury in the hair of ASD patients in
America was signiﬁcantly lower than healthy subjects while in Asia,
Africa, and Europe the results were not statistically signiﬁcant. Sub-
group analysis also revealed that the concentration of mercury in the
Fig. 1. PRISMA ﬂow diagram of study identiﬁcation,
inclusion and exclusion.
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urine and whole blood did not diﬀer between ASD patients and healthy
subjects in America as well as the other continents.
4. Discussion
The relationship between mercury and ASD has always been a topic
of controversy among researchers. Concerns about the relationship
between mercury and ASD began in the 1990s when investigators re-
ported on a suspected relationship between vaccines containing mer-
cury and the risk of autism [64]. In 2001, the Institute of Medicine
(IOM) [65] also stated that it was biologically plausibly for exposure to
mercury to be as a risk factor for neurodevelopmental disorders such as
autism.
Increased level of mercury in the body of patients with autism
compared to healthy subjects has been proven in many studies; how-
ever, some studies demonstrated no statistically signiﬁcant diﬀerence.
Results of current meta-analysis revealed that the concentrations of
mercury were signiﬁcantly higher in the blood, RBC, and brain tissue of
ASD patients compared to healthy subjects. There are powerful detox-
iﬁcation mechanisms to deal with toxic agents and protect the organs
from their damages. Glutathione-S-transferase (GST) is an important
example of these mechanisms. GST detoxiﬁes the xenobiotics, drugs,
and toxins and inhibits accumulation of toxic agents in the organs. It
also activates some mitogen-activated protein kinases which are in-
volved in the diﬀerentiation and development of cells [47]. The other
mechanism for excreting mercury involves metal binding to glutathione
Table 1
Characteristics of studies enrolled in meta-analyses.
Study/Year Country Study
qualitya
No. of subjects Age (mean ± SD), year Gender Tissue Method of Hg
measurement
Case Control Case Control
Wecker et al. [25] USA 7 12 22 5.67 ± 2.39 4.18 ± 1.83 Male & female Hair AAS
Bradstreet et al. [26] USA 8 221 18 6.25 ± 3.06 8.85 ± 3.25 Male & female Urine ICP-MS
Holmes et al. [27] USA 8 94 45 7 ± 3.25 7 ± 1.02 Male & female Hair ICP-MS
Ip et al. [10] Hong Kong 8 82 55 7.2 ± 0.2 7.8 ± 0.4 Male & female Hair, blood AAS
Al-Ayadhi [28] Saudi Arabia 7 65 80 9 ± 2.42 7.2 ± 6.21 Male & female Hair AAS
Fido and Al-Saad [29] Kuwait 5 40 40 4.2 ± 2.2 4.3 ± 2.6 Male Hair ICP-MS
Adams et al. [30] USA 9 51 40 7.1 ± 3 7.5 ± 3 Male & female Hair ICP-MS
Kern et al. [31] USA 9 45 45 3 ± 1.4 3 ± 1.4 Male & female Hair ICP-MS
Mostafa and Refaei [11] Egypt 7 40 40 5.38 ± 1.85 5.25 ± 1.80 Male & female Blood HG-AAS
Adams et al. [32] USA 8 78 31 1.38 ± 0.37 1.37 ± 0.42 Male & female Hair CV-AFS
Sajdel-Sulkowska et al.
[33]
USA 7 6 9 12.1 ± 8.09 13.4 ± 7.14 Male & female Cerebella CV-AFS
Williams et al. [34] Egypt 7 15 16 2–6b 2–6b Male & female Hair ICP-MS
El-Baz et al. [35] Egypt 8 32 15 6.75 ± 3.26 5.53 ± 2.75 Male & female Hair HG-AAS
Geier et al. [36] USA 8 83 89 7.3 ± 3.7 11.4 ± 2.2 Male & female RBC CV-AAS
Hertz-Picciotto et al. [37] USA 8 249 143 2–5b 2–5b Male & female Blood ICP-MS
Majewska et al. [38] Poland 8 30 19 3.6 ± 0.55 3.5 ± 0.44 Male & female Hair CV-AAS
Woods et al. [39] USA 7 59 59 6.01 ± 2.14 6.39 ± 3.06 Male Urine CV-AFS
Woods et al. [39] USA 7 5 55 4.60 ± 1.82 6.93 ± 2.85 Female Urine CV-AFS
Blaurock-Busch et al. [40] Saudi Arabia 7 25 25 5.29 ± 1.90 6.25 ± 2.31 Male & female Hair, urine ICP-MS
Elsheshtawy et al. [41] Egypt 8 32 32 4.1 ± 0.8 4 ± 0.8 Male & female Hair HG-AAS
Obrenovich et al. [42] USA 8 26 39 <6 <6 Male & female Hair ICP-MS
Priya and Geetha [43] India 7 50 50 4–12b 4–12b Male & female Hair CV-AAS
Albizzati et al. [44] Italy 8 17 20 11.5 ± 3.20 10.4 ± 3.05 Male & female Hair, urine, blood ICP-MS
De Palma et al. [13] Italy 8 44 61 9 ± 4 8.4 ± 3.1 Male & female Hair ICP-MS
Wright et al. [14] United
Kingdom
8 54 121 9.6 ± 3.6 8.8 ± 2.4 Male & female Urine ICP-MS
Adams et al. [45] USA 6 55 44 10.0 ± 3.1 11.0 ± 3.1 Male & female Urine, blood, RBC ICP-MS
Rahbar et al. [46] Jamaica 8 65 65 2–8b 2–8b Male & female Blood ICP-MS
Alabdali et al. [47] Saudi Arabia 7 58 32 7 ± 2.34 7.2 ± 2.14 Male RBC AAS
Hodgson et al. [48] Oman 6 27 27 5.3 ± 1.5 5.5 ± 1.4 Male & female Hair ICP-MS
Khan et al. [49] USA 9 10 11 4–15b 5–16b Male & female Cerebella,
brainstem
ICP-MS
Yassa [50] Egypt 5 45 45 2–10b 2–10b Male & female Hair, blood ICP-MS
Yau et al. [15] USA, Mexico 9 76 147 3–4b 3–4b Male & female Blood ICP-MS
Macedoni Lukšič et al.
[51]
Slovenia 8 42 14 6.2 ± 3 6.6 ± 3.7 Male & female Blood CV-AAS
McKean et al. [52] USA 8 164 58 2–5b 2–5b Male & female Blood ICP-MS
Metwally et al. [53] Egypt 6 55 75 4.01 ± 1.91 4.02 ± 1.33 Male & female Urine ICP-MS
Mohamed et al. [54] Egypt 7 100 100 6.24 ± 2.43 6.80 ± 3.04 Male & female Hair HG-AAS
Mostafa and Al-Ayadhi
[55]
Egypt 6 100 100 8.1 ± 1.7 8.3 ± 1.6 Male & female Blood CV-AAS
Domingues et al. [56] Italy 8 21 19 6.9 ± 2.33 7.4 ± 2.11 Male & female Hair ICP-OES
El-Ansary [57] Saudi Arabia 7 20 20 7 ± 4 7 ± 4 Male & female RBC AAS
Khaled et al. [12] Egypt 8 40 40 4.12 ± 0.94 5.23 ± 1.25 Male & female Blood CV-AAS
Mostafa et al. [58] Egypt 7 84 84 6.8 ± 1.5 7 ± 1.8 Male & female Blood CV-AAS
El-Ansary et al. [59] Saudi Arabia 7 35 30 7.0 ± 2.34 7.2 ± 2.14 Male RBC AAS
Li et al. [60] China 7 180 184 5.06 ± 1.37 6.12 ± 1.69 Male & female Blood AFS
Skalny et al. [61] Russia 8 74 74 5.12 ± 2.36 5.11 ± 2.34 Male & female Hair ICP-MS
Skalny et al. [62] Russia 8 33 33 5.0 ± 1.7 5.0 ± 1.7 Male Hair ICP-MS
Abbreviations; AAS, Atomic absorption spectrometry; AFS, Atomic ﬂuorescence spectroscopy; CV-AAS, Cold vapor-Atomic absorption spectrometry; HG-AAS, Hydride generation-Atomic
absorption spectrometry; ICP-MS, Inductively coupled plasma-Mass spectrometry; ICP-OES, Inductively coupled plasma-Optic emission spectrometry; RBC, Red blood cells.
a Study quality was assessed based on the Newcastle-Ottawa scale [17].
b Minimum-maximum value (year).
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Fig. 2. Forest plot of the association between hair mercury level and ASD without studies of Fido and Al-Saad [29], Hodgson et al. [48], and Yassa [50].
Fig. 3. Forest plot of the association between urine mercury level and ASD without study of Metwally et al. [53].
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Fig. 4. Forest plot of the association between whole blood mercury level and ASD without studies of Yassa [50] and Mostafa and Al-Ayadhi [55].
Fig. 5. Forest plot of the association between RBC mercury level and ASD without study of Adams et al. [45].
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and then excretion in the bile. It seems that in ASD patients, detox-
iﬁcation mechanisms are impaired and these patients have lower con-
centration of glutathione which lead to retention of toxins in the body
[32,61]. Considering the developmental process of the brain in children
and vulnerability of the blood-brain barrier, mercury can accumulate in
the brain and initiate neuro-inﬂammatory and oxidative stress process
in the brain as well as increasing the levels of brain tissue auto-anti-
bodies which are important factors in the pathophysiology of autism
and other neurodevelopmental disorders [5,66].
Mercury level in the hair of autistic patients and healthy subjects is
one of the most controversial topic among the researchers. Studies
showing higher mercury level in the hair of ASD patients than the
healthy subjects conclude that mercury concentration in the hair is in
compliance with its concentration in the body [28,35,43]. In contrast,
other studies representing lower mercury concentration in ASD subjects
compared to healthy ones infer that ASD patients could not excrete the
toxic agents like mercury from the body [27,41,56]. Our meta-analysis
demonstrated that the concentration of mercury in hair of autistic pa-
tients was signiﬁcantly lower than healthy ones. The low levels of
mercury in the hair of ASD patients may be due to the retention of
mercury inside the cells. A portion of mercury is retained in the cells of
central nervous system. It has been found that cellular thiol groups and
their availability, playing important role in sequestration or detox-
iﬁcation of mercury, are limited in ASD patients compared to healthy
individuals. This limitation can increase the susceptibility of ASD pa-
tients to adverse eﬀects of mercury such as its role in neurodevelop-
mental disorders [5,27]. These ﬁndings and also the results observed in
this study lend support to the hypothesis that as the body tries to get rid
of toxic agents like mercury by excretion of them through the stool,
urine, hair, nail, baby teeth, and other waste materials, there is sig-
niﬁcant dysfunction in such excretory pathways/mechanisms in ASD
patients [13,27,63].
Fig. 6. Forest plot of the association between brain mercury level and ASD.
Table 2
Results of the association between autism and mercury level based on continent.
Tissue Continent No. of studies Eﬀect size (95% CI) P value I2 (%) Q-statistics (P)
Hair America 7 −0.239 (−0.42, −0.058) 0.010 2.30 0.408
Asiaa 6 0.096 (−0.233, 0.425) 0.567 0 0.965
Europe 4 −0.002 (−0.341, 0.338) 0.993 0 0.840
Africab 3 −0.317 (−1.611, 0.976) 0.631 47.2 0.076
Urine America 4 0.706 (−0.504, 1.917) 0.253 44.9 0.142
Othersc 3 0.482 (−0.352, 1.315) 0.257 21.1 0.281
Blood America 7 −0.011 (−0.446, 0.423) 0.959 0 1.00
Othersd 7 0.737 (0.290, 1.183) 0.001 40.3 0.123
a Analysis performed without studies of Fidio and Al-Saad [29], and Hodgson et al. [48].
b Analysis performed without study of Yassa [50].
c Analysis performed without study of Metwally et al. [53].
d Analysis performed without studies of Yassa [50] and Mostafa and Al-Ayadhi [55].
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In India, Priya and Geetha [43] evaluated the mercury level of nails
in 45 ASD patients and 50 healthy subjects and showed that the con-
centration of mercury was signiﬁcantly higher in the nails of ASD pa-
tients compared to healthy subjects. In USA, Adams et al. [63] con-
ducted a study to compare the concentration of mercury in baby teeth
of 15 ASD patients and 11 healthy subjects. They represented that au-
tistic children have higher level of mercury in their teeth compared to
healthy ones. However, in another study in USA, Abdullah et al. [9]
found no signiﬁcant diﬀerence between the concentration of mercury in
the teeth of ASD subjects and healthy ones. Regarding the lack of en-
ough data about the concentration of mercury in the nail and baby
teeth, we did not perform the analyses in these tissues. It seems that
more studies should be performed on the concentration of mercury in
hair, nail, and other excretory materials of ASD patients worldwide.
Yoshimasu et al. [67] conducted a meta-analysis to evaluate the
association between prenatal or early infancy exposures to mercury and
autism. They concluded that exposure to thimerosal vaccines (con-
tained ethyl mercury) did not associate with ASD, while there was a
signiﬁcant association between environmental exposure to mercury and
ASD. To our knowledge, our meta-analysis is the ﬁrst study aimed to
assess the relationship between mercury levels in the diﬀerent tissues
and ASD. We infer that exposure to mercury increase the risk of ASD
and critical care is necessary to reduce the incidence of ASD.
The current study has also some limitations:
– The major problem with case-control studies is the temporal re-
lationship between exposure and outcome. It is possible, for ex-
ample, that older children with ASD may exhibit more mouthing
behavior than healthy controls, leading to increased levels of mer-
cury (and other pollutants) in their biological tissues.
– Lack of enough studies for nail and teeth
– Diﬀerences in the diagnostic criteria for ASD in the studies.
– Measurement of total mercury but not inorganic or organic forms
separately in the studies: it is believed that exposure to organic
forms of mercury such as ethylmercury, used as vaccine preservative
thimerosal, and methylmercury, found primarily in seafood pro-
ducts, are mostly implicated in the ASD.
– Few number of studies performed outside the America continent.
5. Conclusion
Results of the current meta-analysis revealed that mercury is a
causal factor in the etiology of ASD. The higher levels of mercury in the
blood, RBC, and brain tissue of ASD patients observed in this study
signiﬁcantly support this conclusion. Furthermore, signiﬁcant evidence
supports impaired mercury detoxiﬁcation and excretory mechanisms in
ASD patients. Finally, future worldwide studies should be conducted to
examine the concentration of mercury in urine, hair, nail, baby teeth,
and other excretory materials of ASD patients.
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